Navigation Links
NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
Date:4/3/2009

Minimally Invasive Treatment for Varicose Veins to be showcased at National Health Service EXPO

SAN JOSE, Calif., April 3 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, today announced that the UK NHS National Innovation Centre has identified the VNUS Closure(R) procedure as a select innovative technology that is bringing benefits to National Health Service (NHS) hospitals and patients. The VNUS Closure procedure is a minimally invasive treatment for patients suffering with symptomatic varicose veins and venous reflux, and has been demonstrated in numerous comparative studies to offer advantages over conventional vein stripping surgery. The technique will be showcased at the NHS EXPO Meeting on June 18-19, 2009.

"Our treatment alternative has enabled many NHS Trusts to perform a very common operation virtually pain-free in a simple treatment room in around 30-40 minutes without a general anaesthetic or overnight stay," said Michael Branagan-Harris, UK Managing Director for VNUS Medical Technologies UK Ltd. "This in turn has enabled hospitals to save money by freeing up expensive resources such as operating theatres, ward beds and staff for more invasive procedures."

"It is clear that by freeing up hospital operating theatres and reducing both treatment and recovery times, this technique offers significant benefits for both the patient and the NHS," said Mr. Brian Winn, Head of Technology & Product Innovation at the NHS National Innovation Centre.

"In my view the VNUS Closure procedure is the preferred technique to treat venous reflux because it requires no special modifications to operating areas, is well tolerated by patients, requires minimal post-procedure analgesia and is highly effective at permanently closing the vein," said Ian Franklin, Consultant Vascular Surgeon from Charing Cross NHS Hospital & Imperial College London.

Varicose veins are caused by increased pressure in the legs as a result of venous reflux and faulty valves in the leg veins. Left untreated, venous reflux can lead to painful varicose veins, swelling in the lower limbs, and skin problems, such as itching, redness, eczema, and leg ulcers.

For the past century, the traditional treatment for varicose veins has been a technique called vein stripping, which is carried out under general anaesthesia in operating theatres, and sometimes involves an overnight stay in a hospital bed. This treatment involves a groin incision and the complete removal of the saphenous vein, and recovery can be lengthy and uncomfortable. Surgeons in the NHS perform around 37,000 varicose vein stripping procedures every year.

The VNUS Closure procedure consists of inserting a thin radiofrequency (RF) catheter into the diseased vein through a small incision. The catheter then heats the diseased vein sequentially in 7-centimeter segments, sealing it from the inside and effectively closing it down. Blood returning to the heart then naturally reroutes through healthy veins containing normal valves.

"We are delighted that the NHS National Innovation Centre is showcasing our technology at the forthcoming EXPO meeting, and appreciate their support in driving the acceptance and adoption of our innovative treatment through NHS Hospitals across the UK," said Brian Farley, President and CEO of VNUS Medical Technologies, Inc. "With the support of the NHS, Charing Cross NHS Hospital in London and Ian Franklin, we are continuing our programs to train more surgeons in the VNUS Closure procedure so that more UK patients can benefit from this proven technology."

Additional information about the VNUS Closure Procedure can be found at www.vnus.com. To learn more about the NHS National Innovation Centre please visit www.nic.nhs.uk.

ABOUT VNUS MEDICAL TECHNOLOGIES, INC.

Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (NASDAQ: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease.


'/>"/>
SOURCE VNUS Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
2. Mayo Clinic: Retired National Football League Linemen Have High Incidence of Sleep Apnea
3. DaVita Abstracts Accepted Into National Kidney Foundations 2009 Spring Symposium
4. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
5. Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
6. Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials
9. Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients
10. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
Breaking Medicine News(10 mins):